This recombinant monoclonal antibody is developed as a research-grade biosimilar to atibuclimab, targeting CD14, a glycosylphosphatidylinositol-anchored membrane protein and pattern recognition receptor expressed primarily on monocytes and macrophages. CD14 functions as a co-receptor for lipopolysaccharide (LPS) detection, playing a critical role in innate immune responses and inflammatory signaling pathways. Through its interaction with toll-like receptor 4 (TLR4), CD14 mediates cellular responses to bacterial endotoxins and is implicated in various inflammatory conditions, sepsis, atherosclerosis, and immune-mediated disorders. Dysregulated CD14 expression has been associated with chronic inflammatory diseases and altered immune homeostasis.
Atibuclimab represents a therapeutic monoclonal antibody designed to modulate CD14-mediated inflammatory responses. This biosimilar antibody provides researchers with a valuable tool for investigating CD14 biology, studying monocyte and macrophage function, exploring innate immune mechanisms, and evaluating potential therapeutic interventions in inflammation-related research models. The antibody enables detailed examination of CD14's role in pathogen recognition, cytokine production, and immune cell activation across various experimental systems.
Email: support@cusabio.com
Distributors Worldwide